The A1c lowering ability of the different SGLT2 inhibitors is similar but A1c is reduced to a slightly greater extent by high-dose canagliflozin, which is probably a result of its additional action of inhibiting SGLT1 in the intestine decreasing dietary glucose absorption (138,139,141)
Besides, pancreatic -cells start to function abnormally and secrete an excessively large amount of glucagon in patients with type 1 diabetes mellitus, which further aggravates the metabolic disorders already caused by insulin deficiency (11)
So, is this dual impact of the incretin receptor agonists enough to consider it a paradigm shift in diabetes management
Treatments rely on science, not trends, matched closely to personal skin issues
Oui, les commandes sont traites rapidement et livres de manire fiable sur lensemble du territoire franais.